Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.
Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
Abstract titles reveal some of ASCO’s key datasets.
